In an interview with Targeted Oncology, Daniel Heng, MD, of the University of Calgary, discusses the recent FDA approval of belzutifan (Welireg) plus lenvatinib (Lenvima) for patients with…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Yu-Wei Chen, MD, MS, Assistant Professor of Medicine, University of California, San Diego, La Jolla, California, reviews later-line treatment strategies for advanced renal cell carcinoma (RCC) in the…
Empowering You – Treating Locally Advanced Renal Cell Carcinoma The Kidney Cancer Association and Mayo Clinic held a virtual education event for patients and caregivers on January 31,…
Jodi K. Maranchie, MD, FACS, Associate Professor of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, reviews whether cytoreductive nephrectomy still has a role in metastatic renal…
Empowering You – Treating Advanced/Metastatic Renal Cell Carcinoma The Kidney Cancer Association and Mayo Clinic held a virtual education event for patients and caregivers on January 31, 2026.…
David Simel, MD, and William Kim, MD, explore renal cell carcinoma in this JAMA Clinical Review podcast. They discuss key insights from the 2019 Nobel Prize research on…
This video explores the evolving role of biomarkers in kidney cancer treatment, especially as more therapies become available for both metastatic and adjuvant settings. Key questions include which…
Medicosis Perfectionalis dives into renal cell carcinoma (RCC), a type of kidney cancer. The tutorial covers RCC’s origins in proximal renal tubular cells, the most common subtype (clear…
